Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2020

View Archived Issues

Mink stole show from bats in new COVID trouble

Cholesterol drug affects checkpoint blockade via MHC1

FDA accepts IND application for LY-3561774

2,4-Diamino-6-methylpyrimidines as novel histone lysine methyltransferase G9a/GLP inhibitors

Novel series of triaryl compounds acting as 20S proteasome inhibitors with subunit selectivity

Spectrum Antimicrobials developing SPC-069 for pulmonary infections

Topline phase III data reported for NurOwn in ALS

FDA issues complete response letter related to ALKS-3831 manufacturing records review

FDA clears IND for phase II/III study of RHB-107 in symptomatic COVID-19 disease

Vimpat CV approved in U.S. for PGTCS, pediatric use for Vimpat injection expanded

Alis Pharma patents fetal tissue extracts

New mutant EGFR inhibitors described by Bayer, The Broad Institute, Dana-Farber Cancer Institute

Mirati Therapeutics identifies new polycomb protein EED inhibitors

Rutgers describes new zinc complexes

Targeting ACPAs in rheumatoid arthritis

New bromodomain-containing protein inhibitors discovered by ConverGene, NIH

Results reported from first trial of NJH-395 in non-breast HER2-positive advanced malignancies

The unusual suspects: Test rapidly diagnoses any known pathogen from any available body fluid

First-in-human phase Ib data presented for CM-101 in patients with NAFLD

Early clinical data on SAR-441000 support further evaluation

EMA and Swissmedic begin rolling reviews of COVID-19 vaccine candidate mRNA-1273

FS-118 demonstrates early signs of clinical efficacy in PD-(L)1-resistant advanced cancer

IND cleared in U.S. for Vivet's phase I/II study of VTX-801 for Wilson's disease

FDA lifts clinical hold on phase I trial of UCARTCS1 for multiple myeloma

Phase I data pave way for phase II evaluation of PureTech's LYT-100

Avrobio announces pipeline update and new program in Gaucher disease type 3

New phase Ib study to evaluate motixafortide for ARDS

Final efficacy analysis shows phase III study of BNT-162b2 meets primary efficacy endpoints

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...